Zomedica (ZOM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, to be held virtually via live audio webcast, allowing real-time participation and voting for registered shareholders and proxyholders.
Notice-and-access model used for meeting materials, with instructions for accessing documents online and options for requesting paper copies.
Shareholders encouraged to vote in advance by proxy, with detailed instructions provided in the management information circular.
Voting matters and shareholder proposals
Election of eight director nominees to serve until the next annual meeting.
Ratification of Grant Thornton LLP as independent registered public accounting firm for 2026.
Advisory vote to approve executive compensation for named executive officers.
Amendment to company by-laws regarding quorum requirements for adjourned meetings.
Consideration of any other matters properly brought before the meeting.
Board of directors and corporate governance
Board recommends voting "FOR" all director nominees and all other proposals on the agenda.
Latest events from Zomedica
- Q1 revenue rose 35% to $8.8M, net loss narrowed, and margins and cash position remained strong.ZOM
Q1 20266 May 2026 - Strong growth and innovation in animal health technology drive expanding market leadership.ZOM
Investor presentation1 May 2026 - Virtual meeting to vote on directors, auditor, executive pay, and by-law amendment; Board is majority independent.ZOM
Proxy filing27 Apr 2026 - AI-driven platforms and recurring revenue fuel growth, with profitability targeted by 2027.ZOM
Status update21 Apr 2026 - Virtual meeting to vote on directors, auditor, executive pay, and by-law changes; board is majority independent.ZOM
Proxy filing14 Apr 2026 - Record revenue growth and strong margins, with new segments and cost controls driving performance.ZOM
Q4 202516 Mar 2026 - Profitability targeted for 2027, with strong R&D and product innovation fueling growth.ZOM
Status update27 Feb 2026 - Innovative veterinary solutions and recurring revenue drive high growth and margin expansion.ZOM
Small-Cap Growth Virtual Investor Conference1 Feb 2026 - Q2 revenue up 2% to $6.1M, but net loss surged on $16M impairment; margin reached 71%.ZOM
Q2 20241 Feb 2026